XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Retained Earnings
Unearned ESOP Shares
Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Jun. 30, 2021   16,636,483        
Balance at beginning of period at Jun. 30, 2021 $ 396,519 $ 167 $ 160,582 $ 240,075 $ (5,819) $ 1,514
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 29,628     29,628    
Cash dividends declared on common stock (4,094)     (4,094)    
Common stock repurchased (in shares)   (1,095,763)        
Common stock repurchased (32,318) $ (11) (32,307)      
Forfeited restricted stock (in shares)   (12,000)        
Retired stock (in shares)   (11,335)        
Retired stock $ (345)   (345)      
Granted restricted stock (in shares)   40,123        
Stock issued for RSUs (in shares)   7,118        
Exercised stock options (in shares) 413,636 413,636        
Exercised stock options $ 6,081 $ 4 6,077      
Share-based compensation expense 1,407   1,407      
ESOP compensation expense 1,164   767   397  
Other comprehensive income (loss) (2,911)         (2,911)
Balance at end of period (in shares) at Mar. 31, 2022   15,978,262        
Balance at end of period at Mar. 31, 2022 395,131 $ 160 136,181 265,609 (5,422) (1,397)
Balance at beginning of period (in shares) at Dec. 31, 2021   16,303,461        
Balance at beginning of period at Dec. 31, 2021 401,746 $ 163 147,552 258,986 (5,555) 600
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 8,023     8,023    
Cash dividends declared on common stock (1,400)     (1,400)    
Common stock repurchased (in shares)   (419,931)        
Common stock repurchased (12,915) $ (4) (12,911)      
Forfeited restricted stock (in shares)   (2,600)        
Retired stock (in shares)   (8,627)        
Retired stock (270)   (270)      
Granted restricted stock (in shares)   40,123        
Exercised stock options (in shares)   65,836        
Exercised stock options 1,039 $ 1 1,038      
Share-based compensation expense 507   507      
ESOP compensation expense 398   265   133  
Other comprehensive income (loss) (1,997)         (1,997)
Balance at end of period (in shares) at Mar. 31, 2022   15,978,262        
Balance at end of period at Mar. 31, 2022 $ 395,131 $ 160 136,181 265,609 (5,422) (1,397)
Balance at beginning of period (in shares) at Jun. 30, 2022 15,591,466 15,591,466        
Balance at beginning of period at Jun. 30, 2022 $ 388,845 $ 156 126,106 270,276 (5,290) (2,403)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 29,591     29,591    
Cash dividends declared on common stock (4,542)     (4,542)    
Forfeited restricted stock (in shares)   (6,200)        
Retired stock (in shares)   (13,145)        
Retired stock (344)   (344)      
Granted restricted stock (in shares)   57,839        
Stock issued for RSUs (in shares)   13,861        
Stock issued for Quantum merger (in shares)   1,374,646        
Stock issued for Quantum merger $ 37,734 $ 14 37,720      
Exercised stock options (in shares) 351,596 351,596        
Exercised stock options $ 5,131 $ 4 5,127      
Share-based compensation expense 1,465   1,465      
ESOP compensation expense 993   596   397  
Other comprehensive income (loss) $ (631)         (631)
Balance at end of period (in shares) at Mar. 31, 2023 17,370,063 17,370,063        
Balance at end of period at Mar. 31, 2023 $ 458,242 $ 174 170,670 295,325 (4,893) (3,034)
Balance at beginning of period (in shares) at Dec. 31, 2022   15,673,595        
Balance at beginning of period at Dec. 31, 2022 410,155 $ 157 128,486 290,271 (5,026) (3,733)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 6,734     6,734    
Cash dividends declared on common stock (1,680)     (1,680)    
Retired stock (in shares)   (9,066)        
Retired stock (249)   (249)      
Granted restricted stock (in shares)   53,339        
Stock issued for Quantum merger (in shares)   1,374,646        
Stock issued for Quantum merger 37,734 $ 14 37,720      
Exercised stock options (in shares)   277,549        
Exercised stock options 4,066 $ 3 4,063      
Share-based compensation expense 434   434      
ESOP compensation expense 349   216   133  
Other comprehensive income (loss) $ 699         699
Balance at end of period (in shares) at Mar. 31, 2023 17,370,063 17,370,063        
Balance at end of period at Mar. 31, 2023 $ 458,242 $ 174 $ 170,670 $ 295,325 $ (4,893) $ (3,034)